Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.
Diffuse large B-cell lymphoma
Elderly
Geriatric 8
Prediction
Severe adverse events
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
27
04
2020
accepted:
13
11
2020
pubmed:
16
12
2020
medline:
22
6
2021
entrez:
15
12
2020
Statut:
ppublish
Résumé
The management of severe adverse events (AEs) is important in safely and effectively providing chemotherapy to older adults with diffuse large B-cell lymphoma (DLBCL). However, reports on simple and DLBCL-specific predictive models for treatment-related toxicity in elderly individuals are scarce. The aim of this study was to examine the usefulness of Geriatric 8 (G8) in predicting treatment-related severe AEs, nonhematological toxicity, and febrile neutropenia in older adults with DLBCL in real-world practice. We conducted a multicenter, retrospective study on 398 consecutive patients with DLBCL (aged ≥65 years) who received standard therapy at three centers in Japan (University of Fukui Hospital, the Fukui Prefectural Hospital, and the Japanese Red Cross Fukui Hospital), between 2007 and 2017. Multivariate logistic analysis demonstrated that the G8 score was an independent predictive factor for severe AEs. Moreover, a logistic regression model with restricted cubic spline showed a nonlinear association between the incidence of severe AEs and the G8 score. According to receiver operating characteristic analysis, the most discriminative cutoff value of the G8 for the incidence of severe AEs was 11, with an area under the curve value of 0.670. AEs occurred most often in the first course of chemotherapy and decreased as the course progressed. The G8 score, an easy-to-use geriatric assessment tool, can be a useful prediction model of treatment-related severe AEs during standard therapy in older adults with DLBCL. In older patients with diffuse large B-cell lymphoma (DLBCL), to accurately predict the risk of severe adverse events (AEs) in advance is essential for safe and effective treatment. This study demonstrated that the Geriatric 8 score, a simple and established geriatric assessment tool, indicated a high predictive ability for occurrence of therapy-related severe AEs in elderly patients with DLBCL who were treated with standard treatment.
Sections du résumé
BACKGROUND
The management of severe adverse events (AEs) is important in safely and effectively providing chemotherapy to older adults with diffuse large B-cell lymphoma (DLBCL). However, reports on simple and DLBCL-specific predictive models for treatment-related toxicity in elderly individuals are scarce. The aim of this study was to examine the usefulness of Geriatric 8 (G8) in predicting treatment-related severe AEs, nonhematological toxicity, and febrile neutropenia in older adults with DLBCL in real-world practice.
MATERIALS AND METHODS
We conducted a multicenter, retrospective study on 398 consecutive patients with DLBCL (aged ≥65 years) who received standard therapy at three centers in Japan (University of Fukui Hospital, the Fukui Prefectural Hospital, and the Japanese Red Cross Fukui Hospital), between 2007 and 2017.
RESULT
Multivariate logistic analysis demonstrated that the G8 score was an independent predictive factor for severe AEs. Moreover, a logistic regression model with restricted cubic spline showed a nonlinear association between the incidence of severe AEs and the G8 score. According to receiver operating characteristic analysis, the most discriminative cutoff value of the G8 for the incidence of severe AEs was 11, with an area under the curve value of 0.670. AEs occurred most often in the first course of chemotherapy and decreased as the course progressed.
CONCLUSION
The G8 score, an easy-to-use geriatric assessment tool, can be a useful prediction model of treatment-related severe AEs during standard therapy in older adults with DLBCL.
IMPLICATIONS FOR PRACTICE
In older patients with diffuse large B-cell lymphoma (DLBCL), to accurately predict the risk of severe adverse events (AEs) in advance is essential for safe and effective treatment. This study demonstrated that the Geriatric 8 score, a simple and established geriatric assessment tool, indicated a high predictive ability for occurrence of therapy-related severe AEs in elderly patients with DLBCL who were treated with standard treatment.
Identifiants
pubmed: 33320984
doi: 10.1002/onco.13641
pmc: PMC7930418
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
215-223Informations de copyright
© 2020 AlphaMed Press.
Références
Ann Oncol. 2017 Jul 1;28(7):1540-1546
pubmed: 28398499
Am J Hematol. 2017 Oct;92(10):989-996
pubmed: 28612386
Jpn J Clin Oncol. 2020 Dec 16;50(12):1447-1453
pubmed: 32869100
Support Cancer Ther. 2005 Jan 1;2(2):95-7
pubmed: 18628194
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Blood. 2017 Nov 16;130(20):2180-2185
pubmed: 28814386
Crit Rev Oncol Hematol. 2005 Sep;55(3):241-52
pubmed: 16084735
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
PLoS One. 2017 Jun 22;12(6):e0179694
pubmed: 28640844
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Ann Hematol. 2014 Jun;93(6):1031-40
pubmed: 24488257
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
Ann Hematol. 2015 Feb;94(2):357-8
pubmed: 25034876
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685
J Geriatr Oncol. 2019 Mar;10(2):356-358
pubmed: 30333087
J Geriatr Oncol. 2014 Jan;5(1):11-9
pubmed: 24484713
Ann Oncol. 2012 Aug;23(8):2166-2172
pubmed: 22250183
Hematol Oncol. 2018 Oct;36(4):638-644
pubmed: 29882279
Lancet Oncol. 2012 Oct;13(10):e437-44
pubmed: 23026829
Eur J Oncol Nurs. 2014 Dec;18(6):645-8
pubmed: 24954768
Ann Hematol. 2019 Mar;98(3):669-678
pubmed: 30443764
Blood. 2004 Aug 1;104(3):634-41
pubmed: 15016643
Int J Cancer. 2014 Nov 1;135(9):2146-56
pubmed: 24639369
Lancet Oncol. 2011 May;12(5):460-8
pubmed: 21482186
Ann Oncol. 2015 Feb;26(2):288-300
pubmed: 24936581
Blood. 2019 Jul 25;134(4):374-382
pubmed: 31167800
Am J Clin Oncol. 1990;13 Suppl 1:S15-9
pubmed: 2291455
Blood. 2018 Feb 1;131(5):515-524
pubmed: 29141942
J Geriatr Oncol. 2019 Nov;10(6):937-943
pubmed: 31085136
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
J Geriatr Oncol. 2015 Jan;6(1):52-9
pubmed: 25277874
J Clin Oncol. 2014 Jan 1;32(1):19-26
pubmed: 24276775
Cancer. 2012 Jul 1;118(13):3377-86
pubmed: 22072065
Haematologica. 2020 Aug;105(8):e415-e418
pubmed: 31919079
J Clin Oncol. 1998 Jun;16(6):2065-9
pubmed: 9626205
Leuk Lymphoma. 2003 Dec;44(12):2069-76
pubmed: 14959849
J Clin Oncol. 2016 Jul 10;34(20):2366-71
pubmed: 27185838
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Ann Hematol. 2014 Aug;93(8):1305-12
pubmed: 24590536
Clin Oral Investig. 2020 Jun;24(6):1953-1961
pubmed: 31410674
Lancet. 2017 Sep 16;390(10100):1260-1344
pubmed: 28919118
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877